Development of a novel engineered antibody targeting human CD123

Moradi‐Kalbolandi, Shima; Habibi‐Anbouhi, Mahdi; Golkar, Majid; Behdani, Mahdi; Rezaei, Gashin; Ghazizadeh, Leila; Abolhassani, Mohsen; Shokrgozar, Mohammad Ali

doi:10.1016/j.ab.2016.04.017

Cited by 9 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, Morali-Kalbolandi et al developed an anti-CD123 scFv, a molecule that is overexpressed in leukemic stem cells. The anti-CD123 scFv bound and inhibited CD123/IL-3 interactions in an erythroleukemia cell line [ 140 ].…”

Section: Applications Of Scfvsmentioning

confidence: 99%

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Muñoz-López

Ribas‐Aparicio

Becerra-Báez

et al. 2022

Cancers

View full text Add to dashboard Cite

Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.

show abstract

Section: Applications Of Scfvsmentioning

confidence: 99%

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Muñoz-López

Ribas‐Aparicio

Becerra-Báez

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…An anti-EGFR scFv was fused to the plant toxin gelonin (rGel) to get a targeted toxin, which could selectively bind EGFRoverexpressing cells with high affinity and significantly suppressed the tumor growth of human NSCLC (49). Some anti-tumor small molecular drugs have no tumor specificity and high toxicity to normal tissues (50). To overcome this problem, a study showed that nanoparticle surfaces were covered with anti-CD44v6 scFvs, and arsenite ion (As) as the anti-cancer drug was encapsulated inside the nanoparticles, thus providing a safe and targeted carrier for drug delivery.…”

Section: Discussionmentioning

confidence: 99%

Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity

et al. 2020

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) are large and have limitations as cancer therapeutics. Human single-chain variable fragment (scFv) is a small antibody as a good alternative. It can easily enter cancer tissues, has no immunogenicity and can be produced in bacteria to decrease the cost. The chemokine receptor CXCR4 is overexpressed in different cancer cells. It plays an important role in tumor growth and metastasis. Its overexpression is associated with poor prognosis in cancer patients and is regarded as an attractive target for cancer treatment. In this study, a peptide on the CXCR4 extracellular loop 2 (ECL2) was used as an antigen for screening a human scFv antibody library by yeast two-hybrid method. Three anti-CXCR4 scFv antibodies were isolated. They could bind to CXCR4 protein and three cancer cell lines (DU145, PC3, and MDA-MB-231) and not to 293T and 3T3 cells as negative controls. These three scFvs could decrease the proliferation, migration, and invasion of these cancer cells and promote their apoptosis. The two scFvs were further examined in a mouse xenograft model, and they inhibited the tumor growth. Tumor immunohistochemistry also demonstrated that the two scFvs decreased cancer cell proliferation and tumor angiogenesis and increased their apoptosis. These results show that these anti-CXCR4 scFvs can decrease cancer cell proliferation and inhibit tumor growth in mice, and may provide therapy for various cancers.

show abstract

“…According to our previous protocol set up, a sub-library, and phage display library were constructed 24 – 26 . Briefly, using the GenElute™ Gel Extraction Kit (Sigma, Germany), amplified VL and VH fragments were individually mixed, cut, and extracted from the agarose gel.…”

Section: Methodsmentioning

confidence: 99%

Development of an ostrich-derived single-chain variable fragment (scFv) against PTPRN extracellular domain

Dabiri,

Sadeghizadeh,

Ziaei

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

In type 1 diabetes, the immune system destroys pancreatic beta cells in an autoimmune condition. To overcome this disease, a specific monoclonal antibody that binds to pancreatic beta cells could be used for targeted immunotherapy. Protein tyrosine phosphatase receptor N (PTPRN) is one of the important surface antigen candidates. Due to its high sequence homology among mammals, so far, no single-chain monoclonal antibody has been produced against this receptor. In this study, we developed a novel single-chain variable fragment (scFv) against the PTPRN extracellular domain. To this aim, ostrich species was used as a host is far phylogenetically birds from mammals to construct a phage display library for the first time. An ostrich-derived scfv phage display library was prepared and biopanning steps were done to enrich and screen for isolating the best anti-PTPRN binders. An scFv with appropriate affinity and specificity to the PTPRN extracellular domain was selected and characterized by ELISA, western blotting, and flow cytometry. The anti-PTPRN scFv developed in this study could be introduced as an effective tool that can pave the way for the creation of antibody-based targeting systems in cooperation with the detection and therapy of type I diabetes.

show abstract

Development of a novel engineered antibody targeting human CD123

Cited by 9 publications

References 18 publications

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

Anti-CXCR4 Single-Chain Variable Fragment Antibodies Have Anti-Tumor Activity

Development of an ostrich-derived single-chain variable fragment (scFv) against PTPRN extracellular domain

Contact Info

Product

Resources

About